ORs of the responsiveness to GLP-1 analog therapy by clinical characteristics and features of the subjects in multiple logistic regression models
| Model 1 | Model 2 | Model 3 | Model 4 | |
| Age (years) | 1.023 (0.991 to 1.055) P=0.158 | 1.019 (0.983 to 1.057) P=0.304 | 1.027 (0.987 to 1.067) P=0.188 | 1.023 (0.983 to 1.064) P=0.264 |
| BMI (kg/m2) | 0.936 (0.845 to 1.037) P=0.204 | 0.938 (0.846 to 1.039) P=0.218 | 0.959 (0.866 to 1.062) P=0.419 | |
| Gender (male vs female) | 0.438 (0.183 to 1.047) P=0.063 | 0.523 (0.166 to 1.650) P=0.269 | 0.545 (0.172 to 1.724) P=0.301 | |
| Methylation percentage of VTRNA2-1 promoter region | 1.021 (1.005 to 1.038) P=0.009** | 1.026 (1.007 to 1.046) P=0.008** | 1.029 (1.009 to 1.050) P=0.004** | |
| Hypermethylation (≧40%) vs hypomethylation (<40%) in VTRNA2-1 promoter region | 5.264 (1.743 to 15.899) P=0.003* |
**P<0.01.
BMI, body mass index; GLP-1, glucagon-like peptide-1.